Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay172016	Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer SAN DIEGO, May 17, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. Read All »	View HTML Fate Therapeutics Appoints Chris M. Storgard, M.D. as Chief Medical Officer 15.8 KB
Toggle SummaryJun302022	Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer SAN DIEGO , June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Brian T. Powl has been appointed Chief Commercial Officer. Mr. Read All »	View HTML
Toggle SummaryApr022020	Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies ꟷ Collaboration leverages Company’s iPSC product platform and Janssen’s proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates ꟷ ꟷ Fate to receive $50 million upfront payment and $50 million equity investment, plus full funding for the research and Read All »	View HTML
Toggle SummaryNov052020	Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting Four Oral Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event on Friday, December 4 SAN DIEGO , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company Read All »	View HTML
Toggle SummaryDec142011	Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman and Interim CEO San Diego, CA – Fate Therapeutics, Inc. announced today that it has appointed William H. Rastetter Ph.D. as Chairman and Interim Chief Executive Officer. Dr. Rastetter served as Chief Executive Officer of IDEC Pharmaceuticals from December 1986 through November 2003, and as Chairman from May Read All »	View HTML Fate Therapeutics announces the appointment of William H. Rastetter as Chairman and Interim CEO 188.1 KB
Toggle SummaryMar182019	Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors SAN DIEGO , March 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Karin Jooss , Ph.D. Read All »	View HTML
Toggle SummaryJul172019	Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors SAN DIEGO , July 17, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Dr. Read All »	View HTML
Toggle SummaryJan052023	Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents & Receivables; 3-year Operational Runway Provided through Pipeline Prioritization and Expense Reduction Advancing Second-generation CD19-targeted CAR NK Cell Program with Five Novel Synthetic Controls Designed to Increase Potency, Read All »	View HTML
Toggle SummaryDec112017	Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500 SAN DIEGO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that IND-enabling production of FT500 has Read All »	View HTML Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500 25.6 KB
Toggle SummarySep172018	Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies Option-based Collaboration to Develop Two CAR T-Cell Product Candidates Using Fate’s Proprietary iPSC Product Platform SAN DIEGO , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.